{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:56:44Z","timestamp":1794020204768,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.esmoop.2026.106061","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:09:59Z","timestamp":1770329399000},"page":"106061","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Paclitaxel plus cetuximab for the treatment of R\/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trial"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5356-6452","authenticated-orcid":false,"given":"T.","family":"Fuereder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6425-4833","authenticated-orcid":false,"given":"K.","family":"Klinghammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Gr\u00fcnberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Melchardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Kocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gamerith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-1948","authenticated-orcid":false,"given":"C.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Berchtold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Burian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Strobl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.esmoop.2026.106061_bib1","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Machiels","year":"2020","journal-title":"Ann Oncol"},{"issue":"10212","key":"10.1016\/j.esmoop.2026.106061_bib3","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106061_bib4","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.annonc.2022.12.008","article-title":"Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study","volume":"34","author":"Psyrri","year":"2023","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106061_bib5","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1200\/JCO.22.00332","article-title":"Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent\/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651","volume":"41","author":"Haddad","year":"2023","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.esmoop.2026.106061_bib6","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1158\/0008-5472.CAN-14-1913","article-title":"Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer","volume":"74","author":"Parikh","year":"2014","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106061_bib7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106061_bib8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.surg.2012.05.035","article-title":"Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines","volume":"152","author":"Luedke","year":"2012","journal-title":"Surgery"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106061_bib9","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1158\/1078-0432.CCR-12-2426","article-title":"Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients","volume":"19","author":"Srivastava","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106061_bib10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00262-017-1960-8","article-title":"Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy","volume":"66","author":"Lattanzio","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106061_bib11","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/annonc\/mdr367","article-title":"Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and\/or metastatic squamous cell carcinoma of head and neck","volume":"23","author":"Hitt","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.106061_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/srep32946","article-title":"Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent\/metastatic head and neck cancer","volume":"6","author":"Posch","year":"2016","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106061_bib13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1159\/000345453","article-title":"Phase II study of cetuximab in combination with docetaxel in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie","volume":"84","author":"Knoedler","year":"2013","journal-title":"Oncology"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106061_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103476","article-title":"A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody","volume":"9","author":"Koyama","year":"2024","journal-title":"ESMO Open"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.106061_bib15","doi-asserted-by":"crossref","first-page":"6036","DOI":"10.1200\/JCO.2022.40.16_suppl.6036","article-title":"Taxanes plus cetuximab with or without platinum chemotherapy after progression on immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck","volume":"40","author":"Saleh","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2026.106061_bib16","doi-asserted-by":"crossref","first-page":"S797","DOI":"10.1016\/j.annonc.2021.08.1298","article-title":"888P Clinical predictors for survival with the addition of chemotherapy in patients with recurrent-metastatic squamous cell carcinoma of the head and neck after progression on immune checkpoint inhibitors","volume":"32","author":"Issa","year":"2021","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106061_bib17","doi-asserted-by":"crossref","first-page":"e1018","DOI":"10.1002\/onco.13754","article-title":"Safety and efficacy of cetuximab-based salvage chemotherapy after checkpoint inhibitors in head and neck cancer","volume":"26","author":"Cabezas-Camarero","year":"2021","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106061_bib18","doi-asserted-by":"crossref","first-page":"5277","DOI":"10.21873\/anticanres.14532","article-title":"Salvage chemotherapy after nivolumab for recurrent or metastatic head and neck carcinoma","volume":"40","author":"Fushimi","year":"2020","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106061_bib19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/JCMA.0000000000000740","article-title":"Efficacy of cetuximab-containing regimens in the treatment of recurrent\/metastatic head and neck cancer after progression to immune checkpoint inhibitors","volume":"85","author":"Lai","year":"2022","journal-title":"J Chin Med Assoc"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106061_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/CAD.0000000000001006","article-title":"Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study","volume":"32","author":"Kurosaki","year":"2021","journal-title":"Anticancer Drugs"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106061_bib21","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.21873\/invivo.12376","article-title":"Efficacy and safety of paclitaxel combined with cetuximab for head and neck squamous cell carcinoma","volume":"35","author":"Okada","year":"2021","journal-title":"In Vivo"},{"key":"10.1016\/j.esmoop.2026.106061_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2019.104523","article-title":"Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent\/metastatic head and neck squamous cell carcinoma","volume":"101","author":"Pestana","year":"2020","journal-title":"Oral Oncol"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106061_bib23","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3390\/medicina57111151","article-title":"Clinical outcomes of cetuximab and paclitaxel after progression on immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma","volume":"57","author":"Suzuki","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106061_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271907","article-title":"Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: a multicenter clinical study","volume":"17","author":"Wakasaki","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106061_bib25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10147-021-02047-y","article-title":"Outcomes of long-term nivolumab and subsequent chemotherapy in Japanese patients with head and neck cancer: 2-year follow-up from a multicenter real-world study","volume":"27","author":"Yasumatsu","year":"2022","journal-title":"Int J Clin Oncol"},{"issue":"13","key":"10.1016\/j.esmoop.2026.106061_bib26","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1158\/1078-0432.CCR-25-0073","article-title":"INTERLINK-1: a phase III, randomized, placebo-controlled study of monalizumab plus cetuximab in recurrent\/metastatic head and neck squamous cell carcinoma","volume":"31","author":"Fayette","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"10167","key":"10.1016\/j.esmoop.2026.106061_bib27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.esmoop.2026.106061_bib28","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2026.106061_bib29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejca.2019.08.026","article-title":"Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck","volume":"121","author":"Saleh","year":"2019","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106061_bib30","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(17)30421-7","article-title":"Nivolumab versus standard, single-agent therapy of investigator\u2019s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial","volume":"18","author":"Harrington","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106061_bib31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1470-2045(20)30755-5","volume":"22","author":"Guigay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106061_bib32","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/annonc\/mdq077","article-title":"Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and\/or metastatic squamous cell carcinoma of the head and neck","volume":"21","author":"Mes\u00eda","year":"2010","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106061_bib33","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.oraloncology.2012.02.016","article-title":"Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy","volume":"48","author":"Urba","year":"2012","journal-title":"Oral Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106061_bib34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.12788\/j.suponc.0005","article-title":"To treat or not to treat: balancing therapeutic outcomes, toxicity and quality of life in patients with recurrent and\/or metastatic head and neck cancer","volume":"11","author":"Murphy","year":"2013","journal-title":"J Support Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926000037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T23:05:31Z","timestamp":1774047931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926000037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2059702926000037"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106061","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paclitaxel plus cetuximab for the treatment of R\/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106061"}}